Literature DB >> 18302909

Living proof and the pseudoscience of alternative cancer treatments.

Andrew J Vickers1, Barrie R Cassileth.   

Abstract

Michael Gearin-Tosh was an English professor at Oxford University who was diagnosed with multiple myeloma in 1994. He rejected conventional chemotherapeutic approaches and turned to a variety of alternative cancer treatments, particularly those involving nutritional supplements and dietary change. In 2002, Dr. Gearin-Tosh published a book, Living Proof: A Medical Mutiny, recounting his experiences. The book gained significant public and media attention. One chapter was written by Carmen Wheatley, an advocate of alternative cancer treatments. In distinction to Dr. Gearin-Tosh's personal story, Dr. Wheatley makes general claims about cancer treatment that are supposedly based on the research literature. This appears to provide scientific validation for a highly unconventional program of cancer care. However, the scientific case made for alternative cancer treatments in Living Proof does not bear serious examination. There are numerous inaccuracies, omissions, and misrepresentations. Many important claims are either entirely unsubstantiated or not supported by the literature cited. In conclusion, a highly publicized book gives the impression that alternative cancer treatments are supported by scientific research. It also suggests that little progress has been made in the conventional treatment of myeloma. This is highly misleading and may lead to cancer patients rejecting effective treatments.

Entities:  

Mesh:

Year:  2008        PMID: 18302909      PMCID: PMC2630257     

Source DB:  PubMed          Journal:  J Soc Integr Oncol        ISSN: 1715-894X


  9 in total

1.  Long-term results (12 years) of high-dose therapy in 127 patients with de novo multiple myeloma.

Authors:  P Moreau; R Misbahi; N Milpied; N Morineau; B Mahé; M Vigier; M J Rapp; R Bataille; J L Harousseau
Journal:  Leukemia       Date:  2002-09       Impact factor: 11.528

2.  Stress and the development of breast cancer: a persistent and popular link despite contrary evidence.

Authors:  B R Cassileth
Journal:  Cancer       Date:  1996-03-15       Impact factor: 6.860

3.  Disputes conclusions in Hildenbrand study.

Authors:  C Zollman; R Rees
Journal:  Altern Ther Health Med       Date:  1996-07       Impact factor: 1.305

4.  Cancer incidence in parents who lost a child: a nationwide study in Denmark.

Authors:  Jiong Li; Christoffer Johansen; Dorthe Hansen; Jørn Olsen
Journal:  Cancer       Date:  2002-11-15       Impact factor: 6.860

Review 5.  Influence of psychological coping on survival and recurrence in people with cancer: systematic review.

Authors:  Mark Petticrew; Ruth Bell; Duncan Hunter
Journal:  BMJ       Date:  2002-11-09

6.  Five-year survival rates of melanoma patients treated by diet therapy after the manner of Gerson: a retrospective review.

Authors:  G L Hildenbrand; L C Hildenbrand; K Bradford; S W Cavin
Journal:  Altern Ther Health Med       Date:  1995-09       Impact factor: 1.305

7.  A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.

Authors:  M Attal; J L Harousseau; A M Stoppa; J J Sotto; J G Fuzibet; J F Rossi; P Casassus; H Maisonneuve; T Facon; N Ifrah; C Payen; R Bataille
Journal:  N Engl J Med       Date:  1996-07-11       Impact factor: 91.245

8.  Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial.

Authors:  E T Creagan; C G Moertel; J R O'Fallon; A J Schutt; M J O'Connell; J Rubin; S Frytak
Journal:  N Engl J Med       Date:  1979-09-27       Impact factor: 91.245

9.  High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison.

Authors:  C G Moertel; T R Fleming; E T Creagan; J Rubin; M J O'Connell; M M Ames
Journal:  N Engl J Med       Date:  1985-01-17       Impact factor: 91.245

  9 in total
  1 in total

1.  Medicinal mushroom Phellinus linteus as an alternative cancer therapy.

Authors:  Daniel Sliva
Journal:  Exp Ther Med       Date:  2010-05-01       Impact factor: 2.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.